Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.

Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Alkermes, Inc. company was founded in 1987 and is headquartered in Cambridge, Massachusetts. Alkermes, Inc., an integrated biotechnology company, offers extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes. It primarily develops, manufactures, and commercializes VIVITROL, an extended-release Medisorb formulation of naltrexone for the treatment of alcohol dependence, as well as for the treatment of opioid dependence. The company also manufactures RISPERDAL CONSTA, a formulation of risperidone for the treatment of schizophrenia and bipolar disorder. In addition, it is developing Exenatide once weekly for the treatment of type 2 diabetes; ALKS 33, an opioid modulator, which completed phase I randomized, double-blind, and placebo-controlled study for the treatment of addiction, pain, and other nervous system disorders; ALKS 29, an oral combination therapy for the treatment of alcohol dependence; ALKS 27, an inhaled trospium product that is in a phase IIa study for the treatment of chronic obstructive pulmonary disease; and ALKS 36, a co-formulation of an opioid analgesic and RDC-1036 for the treatment of pain. Alkermes, Inc. has collaborative arrangements with Janssen Pharmaceutica, Inc.; Cilag GmbH International; Amylin Pharmaceuticals, Inc.; and Rensselaer Polytechnic Institute.

AlphaRx, Inc., a pharmaceutical company, engages in the research and development of therapeutic products in Canada. The company is developing novel formulations of existing drugs that are insoluble or poorly soluble in water, utilizing its proprietary Bioadhesive Colloidal Dispersion drug delivery systems. Its principal products include Indaflex, a topical cream for the treatment of osteoarthritis of the knee; and Zysolin, an inhaled Tobramycin nanoparticles intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients. Indaflex completed a Phase II Proof of Concept clinical trial and Zysolin is in pre clinical stage. The company was formerly known as Logic Tech International, Inc. and changed its name to AlphaRx, Inc. in January 2000. AlphaRx, Inc. was founded in 1997 and is based in Markham, Canada.

Altea Therapeutics Corporation company was founded in 1998 and is based in Atlanta, Georgia. Altea Therapeutics Corporation, a pharmaceutical company, develops and commercializes transdermal patch technology that delivers therapeutic levels of water-soluble small drugs, therapeutic proteins, carbohydrates, and vaccines through the skin. It provides disease prevention products, insulin skin patches for diabetes, and acute and chronic pain management products. The company also offers PassPort Patch to deliver drugs through the skin. Altea Therapeutics Corporation was formerly known as Altea Development Corporation.

Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

AstraZeneca France does its bit to help its parent, global pharmaceutical powerhouse AstraZeneca, fight diseases from A to Z. In addition to its headquarters at Reuil Malmaison, the company operates an R&D facility for cancer treatments and packaging in Reims. The plant, which produces cancer as well as cardiovascular drugs, sends about a third of its product to Italy, the rest to North Africa and Portugal. The company's Dunkirk production plant makes Pulmicort, Symbicort, Mopral, and INexium in its chemical unit, while the pharmaceutical unit makes Bricanyl and Turbuhaler. Dunkirk ships its finished products to the US. In all AstraZeneca France, which was formed in 1975, makes and ships about 40 drugs.

Banner Pharmacaps, Inc., a drug delivery and specialty pharmaceutical company, engages in the research, development, and manufacture of oral dosage forms for the pharmaceutical health care industry. It develops drug delivery systems and patented technologies, including Soflet Gelcaps, a technology that enrobes tablets with a gelatin or non-animal film; LiquiSoftT Chewable Liquid-Filled Softgels, which is a chewable gel dosage form suitable for pediatric populations; Chewel, a soft chewable gelatin dosage form for pediatric populations; EnteriCare, which are enteric softgels; Versatrol, which is a controlled release softgel technology; and EcoCaps, which are non-animal softgels. It serves pharmaceutical and biotechnology, and consumer healthcare markets. The company was founded in 1994 and is headquartered in High Point, North Carolina. It has drug manufacturing facilities in High Point, North Carolina; Tilburg, the Netherlands; Olds, Canada; and Mexico City, Mexico. It has locations in Mexico, Europe, the Asia/Pacific, the United States, and Canada. Banner Pharmacaps, Inc. operates as a subsidiary of VION N.V.

Biovail Corporation company was founded in 1983 and is headquartered in Mississauga, Canada. Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products principally in the United States and Canada. The company focuses on central nervous system disorders, pain management, and cardiovascular diseases. Its products include Xenazine for the treatment of chorea associated with Huntington's disease; Wellbutrin XL for the treatment of depression in adults; Ultram ER for the management of chronic pain in adults; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; and Cardizem LA that provides blood pressure control.Biovail Corporation company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Zyban for smoking cessation treatment; Monocor for the treatment of hypertension and congestive heart failure; Retavase, a tissue plasminogen activator used in thrombolytic therapy; Glumetza to control hyperglycemia in adult patients with non-insulin dependent and mature onset diabetes; Ralivia for the management of pain; and Nitoman for the treatment of hyperkinetic movement disorders, such as Huntington's chorea, Hemiballismus, Senile Chorea, Tic and Gilles de la Tourette Syndrome, and Tardive Dyskinesia. Its legacy products comprise Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; Ativan for the management of anxiety disorders; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company's generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties.

BioZone Laboratories provides contract development, manufacturing, and marketing of OTC drugs, cosmetics, and supplements. It's OTC products include acne, anti-itch, cough and cold, and wound care products. Supplements include antioxidants, minerals, and vitamins. BioZone also makes more than 20 different kinds of lotions, creams, and ointments. The company has several delivery systems under patent, including LipoSpray, a respiratory drug delivery system, that is designed to deliver the active pharmaceuticals using very tiny encapsulations, liposomes, that allow for more sustained delivery. BioZone was founded by President Daniel Fisher and EVP Brian Keller.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.